Atherosclerosis Drugs Market will Register a Value Tantamount to ~US$ 57.4 Bn by 2027
Transparency Market Research has published a new report on the atherosclerosis drugs market. According to the report, the global atherosclerosis drugs market was valued at ~US$ 45.7 Bn in 2018, and is expected to expand at a CAGR of 2.5% during the forecast period of 2019 to 2027.
Read Report Overview - https://www.transparencymarketresearch.com/atherosclerosis-drugs-market.html
Atherosclerosis is one of the major causes of cardiovascular diseases, and some causative comorbidities associated with it are obesity, diabetes, overweight, unhealthy diet, high blood pressure, and elevated levels of cholesterol. Various drugs, such as statins, are the first line treatment for atherosclerosis. Apart from this, fibrates, calcium channel blockers, beta blockers, angiotensin converting enzyme inhibitors, and diuretics are also used for atherosclerosis treatment. Moreover, PCSK 9 is the new therapy for coronary atherosclerosis plaque formation. Atherosclerosis is also associated with vascular diseases.
In terms of drug class, the cholesterol lowering medications segment held a major share of the global atherosclerosis drugs market in 2018. This segment is likely to maintain its dominance during the forecast period, owing to the increase in use of statins for the treatment of atherosclerosis. The cholesterol lowering medications segment is anticipated to grow at a rapid pace during the forecast period, due to the introduction of new therapy drugs such as PCSK 9 inhibitors. The fibric acid and omega-3 fatty acid derivatives segment held a significant share of the atherosclerosis drugs market, and is likely to expand at a moderate CAGR between 2019 and 2027. The expansion of this segment can be attributed to the rise in the prevalence of cardiovascular events such as stroke, heart failure, etc.
Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73638
Based on distribution channel, the hospital pharmacies segment accounted for a major share of the atherosclerosis drugs market. This segment is projected to grow at a moderate CAGR during the forecast period. The growth of this segment can be attributed to the rise in awareness about cardiovascular treatment, and usage of novel drugs by physicians and patients. The online pharmacies segment held a significant share of the global atherosclerosis drugs market, and is anticipated to grow at a moderate CAGR during the forecast period. Rise in patient preference for online channels due to high adoption of e-Commerce is anticipated to drive the online pharmacies segment.
Global Atherosclerosis Drugs Market: Prominent Regions
North America held a major share of the global atherosclerosis drugs market in 2018. It is primarily driven by factors such as presence of key market players, highly structured healthcare industry, and key developments by market players, such as product launch approvals, key mergers, and acquisitions. For instance, in October 2018, Johnson & Johnson received approval from the U. S. Food and Drug Administration for INVOKANA, to reduce cardiovascular events such as heart attacks and stroke. This product approval enabled the company to strengthen its portfolio in the U.S. In December 2017, Amgen Inc. received approval from the U.S. Food and Drug Administration for REPATHA. This product approval enabled the company to enhance its product portfolio in the U.S. Moreover, high awareness of cardiovascular diseases among people is leading to the adoption of new therapies for atherosclerosis. This factor is anticipated to drive the atherosclerosis drugs market in the region.
Request for Analysis of COVID19 Impact on Atherosclerosis Drugs Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73638
Europe held the second-largest share in the global atherosclerosis drugs market in 2018. The growth of the atherosclerosis drugs market in the region can be attributed to the increase in the prevalence of cardiovascular diseases and strategic developments by key players. For instance, according to the European Cardiovascular Disease Statistics, in Europe, approximately 19% men and 20% women died of ischemic heart diseases in 2017. In May 2018, Amgen, Inc. received approval of the European Commission for REPATHA. This approval enabled the company to widen its product portfolio in Europe.
Asia Pacific accounted for a significant share of the global atherosclerosis drugs market in 2018, and this market in the region is expected to grow at rapid pace during the forecast period. Increase in the number of people suffering from cardiovascular diseases, product approvals, and rise in awareness about cardiovascular diseases are factors anticipated to fuel the growth of the atherosclerosis drugs market in the region. For instance, in January 2019, Amgen Inc. received the National Medical Products Administration (NMPA) approval for REPATHA in China. This product approval is expected to enable the company to enhance its product portfolio and strengthen its market position in China. According to an article published in Circulation Journal, atherosclerosis is common among the Japanese population, and is one of the leading causes of death, reflecting high stroke mortality.
Buy Atherosclerosis Drugs Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=73638
Global Atherosclerosis Drugs Market: Key Players
Key players are expanding their footprint to strengthen their position in the global atherosclerosis drugs market. Increase in the number of patient population and development of new effective treatments for atherosclerosis offer lucrative opportunities to key players to increase their share in the atherosclerosis drugs market. Manufacturers are engaging in new product development, collaborations, and distribution. For instance, in October 2019, Bayer HealthCare, a subgroup of Bayer AG, received approval for Adempas from the U.S. Food and Drug Administration. In May 2019, Pfizer, Inc. received U.S. FDA approval for VYNDAQEL. It reduces cardiovascular mortality and cardiovascular-related hospitalization. In January 2017, Johnson & Johnson acquired Actelion Ltd. This acquisition enabled the company to enhance its cardiovascular and metabolic therapeutic segments.
Prominent players operating in the global atherosclerosis drugs market are GlaxoSmithKline Plc, Sanofi, F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Merck & Co., Inc. (Merck Sharp & Dohme Corp), Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Mylan N.V., Amgen Inc. and Pfizer, Inc.
More Trending Reports by Transparency Market Research –
Animal Genetics Market: https://www.prnewswire.com/news-releases/demand-for-well-bred-animals-with-desirable-genetic-traits-to-drive-animal-genetics-market-transparency-market-research-301016136.html
Read our Case study at https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up
Transparency Market Research,
90 Sate Street, Suite 700,
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atherosclerosis Drugs Market will Register a Value Tantamount to ~US$ 57.4 Bn by 2027 here
News-ID: 2110034 • Views: 258
More Releases from Transparency Market Research
Market Intelligence Report on Calcite Market, 2018-2028
Sales of calcite have witnessed utter proliferation in recent time, in line with the growing demand from paper and pulp sector wherein calcite is highly adopted as a coating and filler material. According to Transparency Market Research analysis, global calcite market is anticipated to register 4.7% CAGR during the study period 2018–2028. The TMR report opines that demand for calcite is highly driven by its significant properties that are paving way
Pearlescent Pigments Market Intelligence Report Offers Growth Prospects
The demand within the global pearlescent pigment market is slated to rise as new creative avenues emerge in the art and craft industry. Several artists have increased the consumption of pearlescent pigments, mainly due to the aesthetic value of these pigments in art forms. The use of these pigments can majorly be attributed to the gloss and shine imparted by these pigments to the design or craft. These pigments exhibit
Aragonite Market to Witness Steady Growth During the Forecast Period 2018-2026
Global Aragonite Market: Overview Aragonite is a carbonate mineral having an orthorhombic crystal system, and very closely resembles calcite. It is considered as the purest form of calcium carbonate. The mineral has garnered wide popularity as gemstone in various parts of the world and has promising healing properties with energy enhancing powers. Aragonite contains traces of magnesium and sand inclusion but rich in calcium carbonate, and is alkaline in nature. It
OEM Insulation Market Growth, Trends and Value Chain 2019-2027 by TMR
OEM Insulation Market – Overview OEM means Original Equipment Manufacturer that indicates to a company that produces a part or a subsystem of a product that is being used by another organization. Thermal insulation or simply insulation allows the product to cut down the heat gain or loss at the minimum by creating a barrier between the surfaces at the varying temperatures. There are wide range of applications and end-use verticals
More Releases for Drug
Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: firstname.lastname@example.org or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: email@example.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning